Original Message
From: Sent: 16 August 2006 09:57
To: Alana Miller
Cc: Subject: NICE Appraisal Cinacalcet

I write to respond on behalf of the Renal Association

The document has been considered by our two experts -

We welcome the recommendation on its use in refractory secondary hyperparathyroidism. This may need more accurate definition - PTH concentration is insufficient. The PTH has to be interpreted in relation to the calcium concentration. A patient with a very low Ca++ may have a very high PTH suppressible into an acceptable range if the calcium is increased by calcium containing binders and vitamin D analogues.

Does your cost analysis take account of potential savings on the use of expensive phosphate binders such as sevelamer?

We have no comments on the remainder of the document and accept its recommendations.